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patients with stage III unresectable non-small cell
lung cancer
Gerald SMA Kerner1*, Leon FA van Dullemen1, Erwin M Wiegman2, Joachim Widder2, Edwin Blokzijl2,
Ellen M Driever2, John WG van Putten3, Jeroen JW Liesker4, Tineke EJ Renkema5, Remge M Pieterman6,
Marc JF Mertens7, Thijo JN Hiltermann1 and Harry JM Groen1Abstract
Background: Stage III unresectable non-small cell lung cancer (NSCLC) is preferably treated with concurrent
schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that
has been studied in phase 1 and 2 studies in this setting. The aim of this study was to describe outcome and
toxicity of low-dose weekly gemcitabine combined with concurrent 3-dimensional conformal radiotherapy
(3D-CRT).
Patients & methods: Treatment consisted of two cycles of a cisplatin and gemcitabine followed by weekly
gemcitabine 300 mg/m2 during 5 weeks of 3D-CRT, 60 Gy in 5 weeks (hypofractionated-accelerated). Overall survival
(OS), progression-free survival (PFS), and treatment related toxicity according to Common Toxicity Criteria of Adverse
Events (CTCAE) version 3.0 were assessed.
Results: Between February 2002 and August 2008, 318 patients were treated. Median age was 64 years (range 36–86);
72% were male, WHO PS 0/1/2 was 44/53/3%. Median PFS was 15.5 months (95% confidence interval [CI], 12.9-18.1)
and median OS was 24.6 months (95% CI., 21.0-28.1). Main toxicity (CTCAE grade ≥3) was dysphagia (12.6%),
esophagitis (9.6%), followed by radiation pneumonitis (3.0%). There were five treatment related deaths (1.6%), two due
to esophagitis and three due to radiation pneumonitis.
Conclusion: Concurrent low-dose gemcitabine and 3D-CRT provides a comparable survival and toxicity profile to other
available treatment schemes for unresectable stage III.
Keywords: Gemcitabine, Stage III NSCLC, Radiotherapy, Concurrent chemoradiotherapyIntroduction
At presentation approximately 30% of patients with non-
small-cell lung cancer (NSCLC) have locally advanced
(stage III) disease [1]. Median overall survival for clini-
cally staged NSCLC stage IIIA is 14 months and for
stage IIIB 10 months with five-year survival of 19% and
7%, respectively [2]. For good performance patients with
unresectable stage III disease, the treatment of choice is
concurrent chemoradiotherapy [3,4]. Different treatment* Correspondence: g.s.m.a.kerner@umcg.nl
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unless otherwise stated.modalities are used in practice, but none is clearly su-
perior to others [5-11].
Gemcitabine is among the strongest radiosensitizing
drugs available, but its use in lung cancer has been li-
mited due to substantial toxicity when combining full-
dose gemcitabine with radiotherapy in treatment of stage
III NSCLC [12,13]. Excess rates of radiation pneumonitis
have been reported using gemcitabine in chemoradiation
for lung cancer in earlier studies that had used 2D radio-
therapy [14,15]. Previously, a phase I trial was conducted
at our institution establishing a safe schedule of concur-
rent weekly 300 mg/m2 gemcitabine and 3D-CRT [16].
These results were confirmed in a phase II trial at our
institution [17].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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toxicity of this treatment regimen in a consecutive co-
hort of patients receiving gemcitabine-based concurrent
chemoradiotherapy for stage III unresectable NSCLC
over a period of 7 years. A subgroup analysis of patients
aged >70 years was planned a priori.
Materials and methods
Patient selection
From February 2002 until December 2009, consecutive
patients with stage III unresectable NSCLC who were
treated with concurrent chemoradiotherapy with gem-
citabine as radiosensitizer referred to one radiotherapy de-
partment from 6 hospitals in the northern part of the
Netherlands were studied. Staging was performed by
whole body 18 F-FDG-PET, contrast enhanced chest CT,
bronchoscopy, endoscopic ultrasound with fine-needle
biopsy and mediastinoscopy. Treatment-related decisions
were made during the weekly multidisciplinary meetings.
The decision for treating these patients with this scheme,
which was regarded as the standard treatment protocol
for NSCLC stage III, was based on physical condition
(performance status according to WHO), co-morbidity,
and expected radiotherapy dose–volume constraints.
Induction chemotherapy
Chemotherapy consisted of two cycles of cisplatin
75 mg/m2 on day 1 and gemcitabine 1125 mg/m2 ad-
ministered intravenously on day 1 and 8 of each 21-day
cycle. This dose of gemcitabine provides the same dose
intensity as the older 3 out of 4 week schedule. Anti-
emetics were ondansetron 8 mg twice daily on days 1
and 2, and dexamethasone 8 mg twice a day on days 1
and 2 of each cycle and aprepitant 125 mg on day 1 and
80 mg on days 2 and 3. The interval between the first
dose of induction chemotherapy and the start of radio-
therapy was 6 weeks.
Radiotherapy with gemcitabine as sensitizer
Patients received 3D-CRT to a total dose of 60 Gy, ad-
ministered over 5 weeks in once daily fractions of 2.4 Gy
five days per week, together with once weekly gemcita-
bine 300 mg/m2. Gemcitabine was omitted when leuco-
cytes were below 3.109/L or platelets below 100.109/L.
The gross target volume (GTV) was delineated on the
planning-CT and included the primary tumor and en-
larged FDG-avid, or pathologically proven lymph nodes.
Until 2005, tumor motion was determined with fluoros-
copy and respective margins were added to the GTV,
thereafter, an internal target volume (ITV) was individu-
ally delineated using a 4D-planning CT. A 5 mm margin
was added to arrive at the clinical target volume, another
6 mm were added for the planning target volume (PTV).
Radiotherapy was delivered using 6 MV photons, thedose was specified at the isocenter and was corrected for
pulmonary heterogeneity. The total radiation dose ad-
ministered corresponded to an equivalent dose of 62 Gy
if it were given in 2 Gy daily fractions.
Dose constraints
The spinal cord dose was constrained to 50 Gy. The
mean lung dose (MLD) should not exceed 20 Gy (uncor-
rected for the slightly higher dose per fraction; this
would equal 21.6 Gy converted to 2Gy/fraction equiva-
lent dose using an alpha/beta of 3Gy in the linear qua-
dratic formula). The V20 (the volume of the total lung
volume receiving ≥ 20 Gy) was constrained to 30% (this
value is challenging to recalculate using the linear-
quadratic formula, but will correspond to a value about
8% higher if given in 2Gy daily fractions).
For patients with high-volume disease, a proof-
planning was made and evaluated for feasibility by the
radiation oncologist. If necessary, the radiation dose was
adapted. If the pulmonary dose constraints were still
considerably exceeded after radiation dose reduction, pa-
tients were excluded from this protocol.
Treatment evaluation
Complete blood cell counts were performed on days 1,
8, and 22 of each induction chemotherapy cycle. On day
1 of each cycle, patient evaluation also included liver
and renal functions, performance status, and toxicity
scoring. During radiotherapy, complete blood cell counts
and toxicity evaluation were performed. Two months
after completion of treatment a response CT scan was
obtained and patients were followed every 3 months
with physical examination, laboratory tests and chest
x-ray. Disease progression was defined according to
RECIST 1.0 criteria [18]. Toxicity (esophagitis, and ra-
diation pneumonitis) related to treatment was retro-
spectively scored using the Common Toxicity Criteria
(CTCAE 3.0) of the National Cancer Institute.
Statistical analysis
Descriptive statistics were used to characterize clinical
features and toxicity. Using the Kaplan-Meier method,
overall survival (OS) and progression-free survival (PFS)
were calculated from the date of diagnosis until death,
loss to follow-up, or first documentation of progressive
disease, respectively. A subgroup analysis in patients
aged over 70 years was performed to evaluate the out-
come in elderly patients. Cox regression analysis was
performed with the variables age, smoking, gender,
histology, radiation dose, WHO performance score and
PTV. A p-value of < 0.05 was considered statistically sig-
nificant. All calculations were performed using SPSS
20.0 (International Business Machines Corp, Armonk,
NY, USA).
Table 1 Patient characteristics
Number of patients
(N = 318) %
Age 64 (36–86)
Male/Female ratio 229/89 72/28


















No induction 25 8
Radiotherapy dose received
30-59 Gy 34 11
60 Gy 284 89
>60 Gy 0 0
During chemoradiotherapy:
Received 5 gemcitabine cycles
and 60 Gy 244 76
Received 1–4 gemcitabine cycles
and/or received less
then 60 Gy 74 24
Table 2 Number of cycles of weekly gemcitabine with
respect to age in stage III NSCLC
Age < 70 Age ≥ 70 Total
1 1 (<1%) 0 1 (<1%)
2 7 (3%) 3 (3%) 10 (3%)
3 9 (4%) 7 (8%) 16 (5%)
4 13 (6%) 11 (12%) 24 (8%)
5 188 (84%) 71 (76%) 259 (84%)
From 8 patients the weekly gemcitabine dosage was not specified.
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Three hundred and eighteen subsequent patients receiv-
ing concurrent chemoradiotherapy with gemcitabine as
a radiosensitizer were studied. Median age was 64 years
(range 36–86); male/female was 72/28%; WHO PS 0/1/2
was 44, 53 and 3%. A total of 93 patients were aged ≥ 70.
Chemotherapy
Two hundred and forty-two patients (76%) received cis-
platin and gemcitabine as induction, 42 (13%) received
carboplatin and gemcitabine, and 9 patients (3%) re-
ceived other schedules. Twenty five (8%) patients did
not receive induction chemotherapy. A total of 259 pa-
tients (81%) received all 5 weekly doses of gemcitabine
during radiotherapy, 244 (76%) received both full dose
gemcitabine and full dose radiotherapy. Fifty-one pa-
tients (16%) received between 1 and 4 gemcitabine ad-
ministrations weekly, mainly due to neutropenia and
thrombocytopenia. For the remaining 8, no information
was available. Patient characteristics are detailed in
Table 1. Interestingly, advanced age did not lead to de-
creasing the concomitant gemcitabine dose (Table 2).
Seven patients (2%) had a tumor resection after
chemoradiotherapy.
Radiotherapy
The radiotherapy dose was 60 Gy in 284 patients (89%)
while less than 60 Gy (range, 29 to 58 Gy) was adminis-
tered in 34 patients (11%). These 34 patients included 17
patients with increased risk of radiation pneumonitis
due to increased V20 and 8 patients who stopped treat-
ment due to radiation related toxicity including 3 pa-
tients with CTC grade 3 esophagitis. Nine patients
received less than 60 Gy for undocumented reasons.
The median PTV was 431 cc with the 90th percentile
at 734 cc. Median V20 was 22.7% and the 90
th percentile
was 31.0%. In patients aged ≥ 70, median PTV was not
different at 411 cc with the 90th percentile at 702 cc.
Median V20 was 23%, with the 90
th percentile at 30.6%.
Survival
Median PFS was 15.5 months (95% CI., 12.9-18.1)
(Figure 1a) and median OS was 24.6 months (95% CI.,
21.0-28.1) with a 5-year survival of 26% (Figure 1b). In
the 244 patients who completed full concurrent treat-
ment, median survival was 26.3 months (95% CI., 21.9-
30.6 months) with a 5-year survival of 27%. In patients
aged ≥ 70, median PFS was 18.7 (95% CI., 10.0-27.4) and
OS was 26.2 months (95% CI., 19.0-33.4) with a 19%
5 year survival rate.
Using univariate Cox analysis, current smoking at
diagnosis, squamous cell histology, higher WHO per-
formance score, male gender and larger PTV, were all
identified as negative factors influencing survival. In
Figure 1 Survival of 318 patients treated with gemcitabine and 3D concurrent radiotherapy. a. Median Progression Free Survival was 15.5
months (95% CI., 12.9-18.1). b. Median Overall Survival was 24.6 months (95% CI., 21.0-28.1) with a 5-year survival of 26%.
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and larger PTV remained as negative factors influencing
survival.Toxicity
Most common toxicities were CTC grade 2 esophagitis
(13.6%), and CTC grade 2 radiation pneumonitis (17.7%)
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with 2 CTC grade 5 events. One patient had an esopha-
geal ulcerative stenosis which resulted in death due to a
massive hemorrhage. The second patient received a
stent for an esophageal stenosis. Later this patient devel-
oped an esophageal-bronchial fistula and died 22 months
later. Three percent (N = 10) of the patients had CTC
grade ≥3 radiation pneumonitis. Three patients had a
grade 5 event (all aged above 70 years). For these three
patients, the PTV was 508, 600 and 578 cc (the 75% per-
centile of the whole cohort was 576 cc), with a V20 of 16,
34, and 30%, respectively. The first patient had no induc-
tion chemotherapy, the two others were treated with in-
duction carboplatin and gemcitabine. In patients who
completed the full chemoradiotherapy (N = 244), 7% had
CTC grade ≥3 esophagitis (including 1 CTC grade 5
event), and 4% CTC grade ≥3 radiation pneumonitis
(including 2 CTC grade 5 events). In patients aged 70
and older (N = 93), 9 patients (9.7%) had CTC grade 3
esophagitis, 4 patients (4.3%) had CTC grade 3 radiation
pneumonitis, and three patients (3.2%) died due to
pneumonitis. The other patients died due to progressive
disease.
Discussion
In this paper, we described outcome and toxicity of
weekly gemcitabine and 5 weeks of 3D-CRT for stage III
NSCLC. The overall median survival was 24,6 months.
Although comparisons between uncontrolled single in-
stitution series should be interpreted with great caution
due to possible variation in patient selection criteria, in
other concurrent chemoradiotherapy regimens median
survival was between 15.3 and 26 months [5-10,19-21].
In addition, esophageal toxicity and radiation pneumon-
itis was also in the same range as other recent studies
with concurrent chemoradiation [5-10,19-21].Table 3 Radiation toxicity CTC ≥ 2 in patients with stage
III NSCLC treated with concurrent gemcitabine and 3D
radiotherapy
Toxicity Total Age < 70 Age ≥ 70
N = 318 % N = 225 % N = 93 %
Esophagitis
CTC 2 43 13.6 32 14.3 11 11.8
CTC 3 29 9.1 20 8.9 9 9.7
CTC 4 1 0.3 1 0.4 0
CTC 5 2 0.6 2 0.9 0
Radiation pneumonitis
CTC 2 52 17.7 38 17.0 14 15.1
CTC 3 6 2.0 2 0.9 4 4.3
CTC 4 1 0.3 1 0.4 0
CTC 5 3 0.9 0 3 3.2In 2003 it had been shown that concurrent low-dose
gemcitabine and 3D-CRT had acceptable toxicity [16].
Subsequently, a phase 2 study showed a median PFS of
12.4 months and OS of 21.6 months with acceptable
toxicity [17]. This was the reason to adopt the here re-
ported regimen as our protocol in the region, because
we were unable to recognize excessive toxicity as re-
ported by others, in our patients. For instance, in a study
from Blanco et al., drug dosage was adapted due to
toxicity while other studies have been closed due to
unacceptable toxicity profiles (especially pulmonary to-
xicity) [15,22,23]. Price et al. investigated gemcitabine at
a lower dosage (100 mg/m2) combined with a lower ra-
diation dosage (55 Gy) given in a shorter time span
(4 weeks) in a study that was prematurely closed due to
slow accrual. There were 2 deaths in the gemcitabine
arm due to acceleration of pre-existing interstitial lung
disease [24]. Of note, in that study a daily fraction-dose
of 2.75 Gy was given and the lung-dose-constraints had
not been adapted for this higher dose per fraction. To
our knowledge, there are no further reports using hy-
pofractionated accelerated radiotherapy combined with
gemcitabine.
The main factors that are important concerning pul-
monary toxicity (i.e. radiation pneumonitis) during che-
moradiation with concurrent low-dose gemcitabine are
not completely understood. Lung dose, the use of con-
formal radiotherapy and the timing of the gemcitabine
dosage are primary candidates. The CALGB 30105 trial
showed that a V20 of 40% was associated with significant
grade 3–5 pulmonary toxicity [25], which would be ex-
pected with any other combination treatment, even with
radiotherapy alone. We observed no unexpected pul-
monary toxicity rates, because at our institute, the con-
straint for V20 was set at a rather conservative 30%
(uncorrected for the slightly higher daily fraction dose of
2.4 Gy) and indeed the vast majority (90%) of treated pa-
tients had a V20 lower than 30%. Elective nodal irra-
diation was completely foregone in the first year of this
study, with no ensuing statistically significant toxicity
differences. However, all three patients in our study who
died due to radiation pneumonitis were aged above 70 –
and had V20 of 16, 34 and 30%, respectively. The
CALGB study also identified older age to be associated
with increased pulmonary toxicity [25].
Also for esophageal toxicity, radiation technique had
been shown to be critical. In a phase 1 study, which ini-
tially started using 2D conformal techniques, but halfway
switched to 3D techniques, the percentage of the
esophagus irradiated to 60 Gy dropped from 68 to 18%,
and grade 2 esophagitis dropped from 5/10 patients to
2/14 patients [14].
Administration of gemcitabine more frequently than
once weekly was also associated with increased toxicity.
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(50 mg/m2) with 3D radiotherapy with elective nodal ir-
radiation of the mediastinum [22]. Of note, the PTV’s in
that study were three times as large as ours due to elec-
tive nodal irradiation. Due to unacceptable toxicity, the
gemcitabine dose was reduced to 35 mg/m2, but even
after this reduction, still more severe CTC grade ≥ 3
esophageal and pulmonary toxicity was observed com-
pared to our study. Our once weekly schedule featured 3
(for 50 mg/ m2) to 4.3 times (for 35 mg/ m2) the cumu-
lative weekly gemcitabine dose [22]. This suggests that
timing of drug administration may trigger toxicity, as
was also demonstrated in our previous phase 1 and 2
clinical trials.
There were a total of 5 (1.6%) non-hematological
grade 5 events in our study, which is comparable to
other mainstream treatment regimens [6,7,10,20].
Conclusions
Treatment of patients with unresectable stage III NSCLC
with cisplatin and gemcitabine followed by concurrent
gemcitabine and 3D conformal radiotherapy was safe and
yielded effectiveness and toxicity rates comparable with
other drugs in our hands. These results are very likely due
to conservative radiation dose-constraints and 3D-con-
formal radiotherapy avoiding irradiation of excessive vol-
umes of uninvolved mediastinal areas. Although age was
not a factor influencing survival and the absolute inci-
dence at 3% grade 5 pneumonitis in patients older than
70 years was what could be expected, patients above
70 years of age should be selected with great caution for
this regimen.
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